Dossier assessment

Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-113
Last updated

Report documents

  1. Extract of dossier assessment

    Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 669 kB, EN, not accessible
  2. Dossier assessment

    Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Dossier assessment

Indication:

Adults with symptomatic chronic heart failure with reduced ejection fraction

Result of dossier assessment:

Hint of non-quantifiable added benefit.

Additional information

Federal Joint Committee (G-BA)

2021.05.20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-113
Commission
Commission awarded on 30.11.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Heart and circulation
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-03-01.

Connected Projects

  1. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-53
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-37
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A17-65
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    Project no.
    A12-18
    Last updated

    Status: Commission completed

  5. Addendum

    Dapagliflozin (heart failure) - Addendum to Commission A20-113

    Project no.
    A21-44
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-11
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-167
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-109
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form